In the tech-dominated venture capital world, 2013 could be called the year of the crowd. With the JOBS Act and the emergence of credible platforms like AngelList, crowdfunding has come into the mainstream in a meaningful way.
Social media, software, and other technology sectors have benefited most from this momentum and this has been the subject of much discussion elsewhere (here is a great post from my partner Fred Destin on the AngelList ‘Revolution’). The impact on biotech, on the other hand, has been more limited and it’s worth exploring more as we contemplate the various funding approaches for early stage healthcare companies.
Image Courtesy of Master isolated images / FreeDigitalPhotos.net
